Retrospective Cohort Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. May 14, 2021; 27(18): 2177-2192
Published online May 14, 2021. doi: 10.3748/wjg.v27.i18.2177
Table 2 Baseline characteristics of patients with and without sustained virologic response and their relationship to treatment efficacy-laboratory parameters
Variable
Total, n = 11938
SVR, n = 11629
Non-SVR, n = 309
P value
Albumin (g/dL)4.37 (4.2-4.45)4.38 (4.29-4.46)4.02 (3.76-4.28)< 0.001
Bilirubin (mg/dL)0.80 (0.79-0.81)0.79 (0.78-0.80)1.06 (0.98-1.15)< 0.001
INR1.10 (1.07-1.12)1.10 (1.07-1.12)1.11 (1.08-1.13)< 0.001
PLT (K/μL)191.47 (190.07-192.85)192.62 (191.22-194.02)147.63 (139.07-156.19)< 0.001
ALT (U/L)78.39 (77.19-79.59)77.92 (76.71-79.13)96.07 (87.16-104.98)< 0.001
Creatinine (mg/dL)0.92 (0.89-0.96)0.93 (0.89-0.96)0.81 (0.79-0.83)0.749
eGFR, n (%)
< 30 mL/min137 (29.2)137 (29.7)0 (0.0)
> 60 mL/min160 (34.0)157 (34.0)3 (37.5)0.252
30-60 mL/min173 (36.8)168 (36.3)5 (62.5)
Hemoglobin (g/dL)14.40 (14.37-14.43)14.40 (14.37-14.44)14.35 (14.15-14.55)0.812
HCV genotype, n (%)
1A434 (3.6)426 (3.7)8 (2.6)
1B9327 (78.1)9147 (78.7)180 (58.3)
220 (0.2)20 (0.2)0 (0.0)< 0.001
31328 (11.1)1221 (10.5)107 (34.6)
4575 (4.8)565 (4.9)10 (3.2)
51 (0.0)1 (0.0)0 (0.0)
62 (0.0)2 (0.0)0 (0.0)
HCV RNA (log10)6.37 (6.34-6.39)6.36 (6.34-6.39)6.39 (6.31-6.46)0.004

  • Citation: Janczewska E, Kołek MF, Lorenc B, Klapaczyński J, Tudrujek-Zdunek M, Sitko M, Mazur W, Zarębska-Michaluk D, Buczyńska I, Dybowska D, Czauż-Andrzejuk A, Berak H, Krygier R, Jaroszewicz J, Citko J, Piekarska A, Dobracka B, Socha Ł, Deroń Z, Laurans Ł, Białkowska-Warzecha J, Tronina O, Adamek B, Tomasiewicz K, Simon K, Pawłowska M, Halota W, Flisiak R. Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study. World J Gastroenterol 2021; 27(18): 2177-2192
  • URL: https://www.wjgnet.com/1007-9327/full/v27/i18/2177.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v27.i18.2177